China NMPA Drug Inspection - Hunan Zhongnan Pharmaceutical Co., Ltd. - Dexamethasone acetate tablets

On March 6, 2020, the Gansu Provincial Drug Administration released the results of an urgent quality sampling inspection conducted in February 2020. This oversight initiative focused on 38 batches of pharmaceuticals critical for the prevention and control of COVID-19. The inspection involved products from numerous manufacturers, including Shijiazhuang Yiling Pharmaceutical Co., Ltd., Sinopharm Rongsheng Pharmaceutical Co., Ltd., and Beijing Tongrentang Co., Ltd. The evaluation was conducted under the regulatory framework of the Chinese Pharmacopoeia (2015 Edition, Parts I, II, and III) and relevant National Drug Standards. Tested products included treatments such as Lianhua Qingwen capsules, Ribavirin injections, and Huoxiang Zhengqi oral liquids. The findings indicated that all 38 sampled batches were fully compliant with established quality standards, and no violations or safety issues were identified. Because all products met the rigorous requirements for safety and efficacy, no required actions or product recalls were necessary. The administration published these results as a proactive disclosure to reassure the public and maintain transparency regarding the integrity of the medical supply chain during the health crisis.